KRAS and familial pancreatic carcinoma: The drug was effective across a panel of pancreatic cancer cell lines (such as BxPc-3, AsPC-1, MiaPaCa-2, L3.6pl, Colo-357, Panc-1, Panc-28) irrespective of their K-ras or p53 mutational status.